Home Abbott

Abbott

MitraClip G4 Receives CE Mark Reports Abbott

The MitraClip G4 system provides physicians in Europe with enhancements to MitraClip's first-of-its-kind clip-based technology, building upon the device's proven delivery system.

First Enrollments in the TactiFlex PAF IDE Study Underway

The study will evaluate the performance of the investigational TactiFlex™ Ablation Catheter, Sensor Enabled™ for people whose AFib symptoms are unable to be managed by medication.

New Late-Breaking Data Highlight Impact of Abbott’s Minimally Invasive Structural Heart Therapies

The data included findings on the MitraClip™ system for transcatheter mitral valve repair and data on two first-in-the-world devices approved in the EU: the TriClip™ system* for transcatheter tricuspid valve repair and the Tendyne™ transcatheter mitral valve implantation system* for people needing a replacement mitral valve.

Abbott Receives FDA Emergency Use Authorization for COVID-19 Molecular Test on New Alinity™ m System

The Alinity™ m system was cleared by the FDA for use with Abbott's HCV (hepatitis C) assay in late March. Abbott is working with hospitals and health systems in the U.S. to install this new instrument, which will help keep up with the growing demand for testing.

TriClip™ Transcatheter Tricuspid Valve Repair System Receives CE Mark

The TriClip Transcatheter Tricuspid Valve Repair System is an investigational device only in the U.S.

Next-Generation Heart Rhythm Management Devices in Europe, Featuring State-of-the-Art Patient App and Bluetooth Connectivity

Abbot reports the devices offer new opportunities for patient engagement and remote monitoring through new smartphone connectivity and connected applications. Additional benefits include a patient preferred design, improved battery longevity, and MRI compatibility.

Tendyne™ Transcatheter Mitral Valve Implantation System Receives CE Mark

This life-changing therapy treats significant mitral regurgitation in patients requiring a heart valve replacement and provides a safe and effective solution for MR patients who are not candidates for open-heart surgery or transcatheter mitral valve repair.

Abbott Receives Expanded Indication From the U.S. FDA for Directional Deep Brain Stimulation System to Treat Parkinson’s Disease

With this approval, Abbott's Infinity DBS is now the only directional DBS system approved for all major targets used to treat movement disorders, Parkinson's disease and Essential Tremor: the subthalamic nucleus (STN), ventral intermediate nucleus (VIM) and GPi.